Abstract 931P
Background
Currently, there is a paucity of validated deep learning methodologies for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma (NPC), both domestically and internationally. Furthermore, advanced techniques such as 2.5D feature extraction and Transformer model establishment remain underexplored in this context.
Methods
MRI images from locally advanced NPC patients diagnosed at two centers between July 2020 and June 2023 were retrospectively collected. Three state-of-the-art (SOTA) models (SegResNet, Unet, and UnetR models) were employed for automatic segmentation of all regions of interest (ROIs), thus generating an automatic segmentation model. Leveraging 2.5D deep learning techniques, tumor image features were extracted and integrated into a transfer learning framework. Subsequently, a Transformer-based model was designed, integrating all individual patient features. Three models were established: a clinical model, a Transformer model, and a fusion model. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the three models, the Transformer model demonstrated superior predictive performance in both the testing (AUC = 0.957) and validation cohorts (AUC = 0.893) compared to the clinical model. Moreover, the fusion model generally matched or surpassed the performance of the Transformer model, particularly in the testing cohort with an AUC of 0.874, indicating that the integration of clinical data with advanced machine learning models can enhance predictive capability.
Conclusions
The fusion model, which combines machine learning with clinical factors, exhibits promising efficacy in predicting short-term outcomes in locally advanced NPC patients following synchronous chemoradiotherapy.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03